SafetyOne44™ and SafetyMax90™, developed by ICE Bioscience, are cutting-edge functional safety panels designed to revolutionize pharmaceutical research. SafetyOne44™ is meticulously tailored for 44 specific molecular targets, offering precision and reliability in assessing drug candidate safety. SafetyMax90™ sets the industry benchmark by encompassing up to 90 diverse molecular targets, ensuring a comprehensive safety assessment. Our panels provide a competitive advantage, enabling early identification of potential off-target adverse drug reactions (ADRs) and informed decision-making, ultimately leading to the development of safer and more effective drugs.
A functional safety panel can effectively illustrate the insights gained from agonist and antagonist assays, providing more comprehensive and informative results. As depicted in the figure below, the SafetyMAX 90 panel was employed to assess Mivebresib's response in both agonist and antagonist modes. Results surpassing the 50% threshold line indicate a clear functional interaction.
Figure. Radar chart depicting the results of the SafetyMax90 panel for Mivebresib.
We value your inquiries and are here to provide you with tailored solutions for your drug discovery and development needs. Whether you have questions, require more information, or are interested in discussing potential collaborations, our team of experts is just a message away.
Feel free to reach out to us.
Address: Bldg 16, Yd 18, Kechuang 13th St, Etown, Tongzhou Dist, Beijing, 100176, China
Email: marketing@ice-biosci.com
Tel：+86-10-67809840
